{"podcast":{"title":"The Academic Minute","slug":"the-academic-minute-1102038","podcast_index_feed_id":1102038,"rss_url":"https://api.substack.com/feed/podcast/7972926.rss","website_url":"https://www.academicminute.org/podcast","image_url":"https://substackcdn.com/feed/podcast/7972926/3de65ac4cfe10a333128ea1e717f3fde.jpg","author":"Academic Minute","episode_count":1000,"summary":"Astronomy to Zoology","last_synced_at":"2026-07-30T14:17:21.893800+00:00","page_url":"https://stenobird.com/podcast/the-academic-minute-1102038"},"episode":{"title":"Raymond Goodrich, Colorado State University - Testing a Promising New Cancer Immunotherapy in Ovarian Cancer Patients","slug":"raymond-goodrich-colorado-state-university-testing-a-promising-new-cancer-immunotherapy-in-ovarian-cancer-patients","published_at":"2026-05-12T04:01:00+00:00","page_url":"https://stenobird.com/podcast/the-academic-minute-1102038/raymond-goodrich-colorado-state-university-testing-a-promising-new-cancer-immunotherapy-in-ovarian-cancer-patients","show_page_url":"https://stenobird.com/podcast/the-academic-minute-1102038","url":"https://www.academicminute.org/p/raymond-goodrich-colorado-state-university","audio_url":"https://api.substack.com/feed/podcast/196912858/2a8e358066f9db7abd50281c6292deb9.mp3","summary":"There may be encouraging news for ovarian cancer patients on the way. Ray Goodrich , professor in the department of Microbiology, Immunology and Pathology at Colorado State University , tells us more. Faculty Bio: Former Executive Director of the Infectious Disease Research Center, Ray Goodrich has been investigating vaccine candidates to combat the pathogens that cause COVID-19, tuberculosis and influenza. He also led the development program for a cancer vaccine targeting solid organ tumors.Goodrich has worked in infectious disease research for more than 35 years, during which he has managed research staff and development programs in the fields of transfusion and transplantation medicine and pathogen reduction technologies. He has been awarded 58 patents covering technology in these areas and is a co-author of 300 peer reviewed articles and abstracts.Goodrich is an active member of the American Chemical Society, serves on the board of directors for the Association for the Advancement of Blood and Biotherapies and serves as a special government employee for the Advisory Committee on Blood and Tissue Safety and Availability at the U.S. Department of Health and Human Services. Transcript: Earlier this year, a biotechnology startup I lead received a patent for an innovative new cancer immunotherapy developed at Colorado State University. More recently, we have been given clearance from the U.S. Food and Drug Administration to begin a Phase 1 clinical trial testing this therapy in humans. The trial will be conducted in ovarian cancer patients at the City of Hope, a leading cancer research center in southern California. We are looking to begin enrolling patients around the end of the year. Here’s how it works: We can extract and expose a patient’s own tumor cells to ultravi…","meta_description":"There may be encouraging news for ovarian cancer patients on the way. Ray Goodrich , professor in the department of Microbiology, Immunology and Pathology…","key_points":[],"chapters":[],"topics":[],"duration_seconds":150,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-academic-minute-1102038/episodes/raymond-goodrich-colorado-state-university-testing-a-promising-new-cancer-immunotherapy-in-ovarian-cancer-patients/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-academic-minute-1102038/raymond-goodrich-colorado-state-university-testing-a-promising-new-cancer-immunotherapy-in-ovarian-cancer-patients.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}